Vale Andrew Baker
Tuesday, 20 March, 2012
Dr Andrew Baker, a veteran of the biotechnology and pharmaceuticals industries, passed away on Sunday March 18 from cancer at the age of 50.
Dr Baker had been a partner with GBS Ventures since 2002, and had sat on the board of several biotechnology companies, including Hatchtech, Spinifex, Verva, Euthymics and Xenome.
He had over 28 years experience in the pharmaceutical and biotechnology industries, and had worked for companies such as Genentech, Bayer and Johnson & Johnson.
More recently, he was involved in founding several listed companies and assisting them with commercial growth and product development, combining his scientific and industry expertise.
Dr Baker held a Bachelor of Science with Honours in genetics from the University of Sydney, and completed his PhD at the Australian National University.
“He was a cherished friend and colleague who will be sadly missed,” Dr Joshua Funder, a friend and colleague of Dr Baker’s, and also a partner at GBS, told Biotech Daily.
Dr Baker is survived by his wife, Nancy, and their children, Claire and Sam.
Anti-inflammatory agent could decrease septic shock mortality
Researchers have discovered a naturally occurring blood protein — a type of...
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
